Chemodosimetry of in vivo tumor liposomal drug concentration using MRI

Magnetic Resonance in Medicine

Volumn 56, Issue 5, 2006, Pages 1011-1018

  Viglianti, Benjamin L ^a   Ponce, Ana M ^a   Michelich, Charles R ^a   Yu, Daohai ^b   Abraham, Sheela A ^c,d   Sanders, Linda ^b   Yarmolenko, Pavel S ^b   Schroeder, Thies ^b   MacFall, James R ^b   Barboriak, Daniel P ^b   Colvin, O Michael ^b   Bally, Marcel B ^c,d   Dewhirst, Mark W ^a,b  

^a Duke University   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemodosimetry; Chemotherapy; Hyperthermia; Liposomes; MRI

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOMES; MAGNETIC RESONANCE IMAGING; TUMORS;

CANCER CHEMOTHERAPY; CHEMODOSIMETRY; DRUG CONCENTRATION; HYPERTHERMIA; INTERSTITIAL FLUID PRESSURES; LINEAR RELATIONSHIPS; REAL TIME EVALUATION; SYSTEMIC ADMINISTRATION;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DOXORUBICIN; LIPOSOME; MANGANESE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MODEL; DOSIMETRY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; EVALUATION; FIBROSARCOMA; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IN VIVO STUDY; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; RAT; TISSUE PRESSURE;

EID: 33750619421     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21032     Document Type: Article

References (39)

1. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000;60:1197-1201.
2. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53:285-305.
3. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000;60:6950-6957.
4. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 2004;51:1153-1162.
5. Abraham SA, Edwards K, Karlsson G, MacIntosh S, Mayer LD, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 2002;1565:41-54.
6. Morgan L, Nolle A. Proton spin relation in aqueous solutions of paramagnetic ions II: Cr+++, Mn++, Ni++, Cu++, and Gd++. J Chem Phys 1959;31:365.
7. Liang Z-P, Lauterbur PC, IEEE Engineering in Medicine and Biology Society. Principles of magnetic resonance imaging: a signal processing perspective. Bellingham, WA: SPIE Optical Engineering Press/IEEE Press; 2000. xv, 416 p.
8. Wehrli FW, Shaw D, Kneeland JB. Biomedical magnetic resonance imaging: principles, methodology, and applications. New York: John Wiley & Sons, Inc., 1988. xvii, 601 p.
9. Grant JP, Wells Jr SA. Tumor resistance in rats immunized to fetal tissues. J Surg Res 1974;16:533-540.
10. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000;60:4440-4445.
11. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027-3032.
12. Dafni H, Gilead A, Nevo N, Eilam R, Harmelin A, Neeman M. Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin. Magn Reson Med 2003;50:904-914.
13. Mayer LD, Hope MJ, Cullis PR, Janoff AS. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta 1985;817:193-196.
14. Fenske DB, Wong KF, Maurer E, Maurer N, Leenhouts JM, Boman N, Amankwa L, Cullis PR. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta 1998;1414:188-204.
15. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000;60:3389-3393.
16. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res 2003;63:5838-5843.
17. de Lussanet QG, Backes WH, Griffioen AW, van Engelshoven JM, Beets-Tan RG. Gadopentetate dimeglumine vs. ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice. Radiology 2003;229:429-438.
18. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, Weissleder R. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63:6838-6846.
19. Shen F, Poncet-Legrand C, Somers S, Slade A, Yip C, Duft AM, Winnik FM, Chang PL. Properties of a novel magnetized alginate for magnetic resonance imaging. Biotechnol Bioeng 2003;83:282-292.
20. Sinha VR, Goyal V, Bhinge JR, Mittal BR, Trehan A. Diagnostic microspheres: an overview. Crit Rev Ther Drug Carrier Syst 2003;20:431-458.
21. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3:912-920.
22. Lymberis SC, Parhar PK, Katsoulakis E, Formenti SC. Pharmacogenomics and breast cancer. Pharmacogenomics 2004;5:31-55.
23. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90:8-11.
24. El-Kareh AW, Secomb TW. A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 2003;5:161-169.
25. Brooks KR, To K, Joshi MB, Conlon DH, Herndon 2nd JE, D'Amico TA, Harpole Jr DH. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 2003;76:187-193; discussion 193.
26. Loni L, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. Br J Cancer 2001;85:1425-1431.
27. Perez CA, Halperin EC, Brady LW, Schmidt-Ullrich RK, editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins: 1998. 2527 p.
28. Bhatnagar A, Hustinx R, Alavi A. Nuclear imaging methods for noninvasive drug monitoring. Adv Drug Deliv Rev 2000;41:41-54.
29. Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D, Thrall DE. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000;:6:3748-3755.
30. Leander P, Mansson S, Ege T, Besjakov J. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model. Acta Radiol 1996;37(3 Pt 1):242-249.
31. Schwendener RA, Wuthrich R, Duewell S, Wehrli E, von Schulthess GK. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest Radiol 1990;25:922-932.
32. Suga K, Mikawa M, Ogasawara N, Okazaki H, Matsunaga N. Potential of Gd-DTPA-mannan liposome particles as a pulmonary perfusion MRI contrast agent: an initial animal study. Invest Radiol 2001;36:136-145.
33. Chu WJ, Simor T, Elgavish GA. In vivo characterization of Gd(BME-DTTA), a myocardial MRI contrast agent: tissue distribution of its MRI intensity enhancement, and its effect on heart function. NMR Biomed 1997;10:87-92.
34. Unger E, Fritz T, Shen DK, Wu G. Manganese-based liposomes. Comparative approaches. Invest Radiol 1993;28:933-938.
35. Unger E, Shen DK, Wu GL, Fritz T. Liposomes as MR contrast agents: pros and cons. Magn Reson Med 1991;22:304-308; discussion 313.
36. Bulte JW, de Cuyper M, Despres D, Frank JA. Short- vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents. J Magn Reson Imaging 1999;9:329-335.
37. Fossheim SL, Fahlvik AK, Klaveness J, Muller RN. Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. Magn Reson Imaging 1999;17:83-89.
38. Bacic G, Niesman MR, Bennett HF, Magin RL, Swartz HM. Modulation of water proton relaxation rates by liposomes containing paramagnetic materials. Magn Reson Med 1988;6:445-458.
39. 2 as a liver specific contrast agent for magnetic resonance imaging. Invest Radiol 1990;25:545-551.